Marcus P. Kelly

Medicine · Health Sciences

17h-index1.1kcitations72works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(41), HER2/EGFR in Cancer Research(37), Advanced Biosensing Techniques and Applications(13), Cancer Research and Treatments(11), Radiopharmaceutical Chemistry and Applications(10)

Publications72 total

Table S2 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Table S1 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Supplementary Data from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Figure S3 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Table S4 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Figure S2 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Data from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Table S3 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Figure S1 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Glioblastoma Cells Use an Integrin- and CD44-Mediated Motor-Clutch Mode of Migration in Brain Tissue
Cellular and Molecular Bioengineering·2024· 5 citedOpen Access
Glioblastoma cells use an integrin- and CD44-mediated motor-clutch mode of migration in brain tissue
2023Open Access
Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
Supplementary Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
Supplementary Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
Supplementary Table S2 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
2023Open Access
Supplementary Figure S5 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
2023Open Access
Supplementary Figure S5 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
2023Open Access
Supplementary Figure S1 - S8 from Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
2023Open Access
Data from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Gavin Thurston(36), William C. Olson(31), Jessica R. Kirshner(29), Frank J. Delfino(26), Sosina Makonnen(25), Carlos Hickey(25), Arthur Kunz(24), Thomas Nittoli(24), Jason T. Giurleo(23), Christopher Daly(17), Julian Andreev(14), Ashique Rafique(11), Marc W. Retter(11), Nithya Thambi(10), Andrés E. Perez Bay(10), Joel W. Martin(10), Terra Potocky(10), Richard Tavaré(10), Shu Mao(10), Feng Zhao(10)